Abivax Shares Dip 2.11% to €97.20, Approaching Oversold Territory
Abivax shares fell by 2.11% this Wednesday, reaching €97.20 amidst a general downturn in European markets. The French biotech, which has seen its stock price increase more than fifteenfold over the past year, is now trading below its short-term moving averages, with its annual 2025 results anticipated on March 23.
Current Market Dynamics and Technical Indicators
Abivax shares declined by 2.11% this Wednesday afternoon, dropping to €97.20 from €99.30 the previous day. This decrease is part of a short-term negative trend: the stock has lost 15.48% over three months and is now significantly below its 50-day moving average of €103.35, indicating a weakening of the bullish momentum that had driven the stock in recent months. The RSI, a measure of the speed and change of price movements, stands at 34, close to the commonly set oversold threshold of 30, suggesting persistent selling pressure. The most immediate technical support is at €93.70, close to the lower Bollinger band at €92.26, a level that might be tested if the downward trend continues. The market environment remains tense, with the VIX recently noted at 29.49, indicating high nervousness. During the session, the CAC 40 fell by 0.49% to 8,017.68 points and the DAX lost 0.94%, creating a challenging climate for growth stocks.
Anticipation for the Annual Financial Results
Attention is turning to March 23, when Abivax is set to reveal its annual financial results for 2025. This announcement will be a significant milestone to assess the financial trajectory of the biopharmaceutical company, which specializes in chronic inflammatory diseases. The expenses related to the clinical development of its drug candidate obefazimod, particularly in ulcerative colitis and Crohn's disease, will be closely examined, as well as the state of available cash reserves. Despite the recent correction, Abivax's stock performance over the past year remains impressive, with an increase of nearly 1,486%, reflecting the interest generated by the progress of its pipeline. The negative beta of -0.49, indicating a low correlation with the overall market, underscores that the stock's performance is primarily driven by company-specific catalysts. The financial calendar then schedules the communication of the first quarter 2026 results on June 1, followed by the half-year results on September 14. The upcoming series of publications will be crucial to gauge Abivax's ability to fund its clinical trials while continuing the development of its flagship molecule.
